At the American Society of Hematology (ASH) meetings in San Francisco last December, I had a chance to sit down with Selena Rush, Director of Clinical Operations at Array Biopharma. Array manufactures the promising new myeloma therapy, ARRY-520 (filanesib). I had two reasons to meet with Selena. First, to get an update on ARRY-520; there […]
Trending Articles
More Pages to Explore .....